July 10, 2005
Amgen's GDNF shows signs of effectiveness LA Times, Business Section,
Letter to the Editor
Regarding "Study adds to dispute over drug by Amgen," July 2:

"Amgen spokeswoman Andrea Rothschild stated that the ability of clinical trial participants with Parkinson's disease to perform day-to-day tasks did not improve when treated with GDNF."

Read the entire letter [12/09; not longer online]

Kristen Suthers
Founder
GDNF4Parkinson's
Washington